Advertisement

Topics

Merck’s CETP inhibitor Anacetrapib meets primary end point in REVEAL study

05:35 EDT 29 Jun 2017 | Pharmaceutical Business Review

Merck announced that the REVEAL (Randomized EValuation of the Effects of Anacetrapib through Lipid modification) outcomes study of anacetrapib met its primary endpoint, significantly reducing major coronary events (defined as the composite of coronary death, myocardial infarction, and coronary revascularization) compared to placebo in patients at risk for cardiac events who are already receiving an effective LDL-C lowering regimen.

Original Article: Merck’s CETP inhibitor Anacetrapib meets primary end point in REVEAL study

NEXT ARTICLE

More From BioPortfolio on "Merck’s CETP inhibitor Anacetrapib meets primary end point in REVEAL study"

Quick Search
Advertisement
 

Relevant Topic

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...